



Erythema Increase Predicts Psoriasis Improvement
after Phototherapy
Trinidad Montero-Vilchez 1,2, Antonio Martinez-Lopez 1,2,*, Alvaro Sierra-Sanchez 2 , Miguel Soler-Gongora 3,




Martinez-Lopez, A.; Sierra-Sanchez, A.;
Soler-Gongora, M.; Jimenez-Mejias, E.;
Molina-Leyva, A.; Buendia-Eisman, A.;
Arias-Santiago, S. Erythema Increase
Predicts Psoriasis Improvement after
Phototherapy. J. Clin. Med. 2021, 10,
3897. https://doi.org/10.3390/
jcm10173897
Academic Editor: Masutaka Furue
Received: 16 July 2021
Accepted: 26 August 2021
Published: 30 August 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Dermatology Department, Hospital Universitario Virgen de las Nieves, Avenida de Madrid, 15,
18012 Granada, Spain; tmonterov@correo.ugr.es (T.M.-V.); alejandromolinaleyva@gmail.com (A.M.-L.);
salvadorarias@ugr.es (S.A.-S.)
2 Instituto de Investigación Biosanitaria GRANADA, 18012 Granada, Spain; alvarosisan@gmail.com
3 Dermatology Department, Faculty of Medicine, University of Granada, 18001 Granada, Spain;
miguelsg@correo.ugr.es (M.S.-G.); abuendia@ugr.es (A.B.-E.)
4 Epidemiology and Public Health Department, Faculty of Medicine, University of Granada,
18012 Granada, Spain; eladiojimenez@ugr.es
* Correspondence: antoniomartinezlopez@aol.com; Tel.: +34-958-023-422
Abstract: Psoriasis is a major global health problem. There is a need to develop techniques to help
physicians select the most appropriate cost-effective therapy for each patient. The main objectives
of this study are (1) to evaluate changes in epidermal barrier function and skin homeostasis after
phototherapy and (2) to explore potentially predictive values in epidermal barrier function and
skin homeostasis to assess clinical improvement after fifteen sessions of phototherapy. A total
of 76 subjects, 38 patients with plaque-type psoriasis and 38 gender- and age-matched healthy
volunteers, were included in the study. Erythema, transepidermal water loss (TEWL), temperature,
stratum corneum hydration (SCH), pH, sebum, and antioxidant capacity were measured before
and after the first and fifteenth phototherapy session. Erythema (401.09 vs. 291.12 vs. 284.52 AU,
p < 0.001) and TEWL (18.23 vs. 11.44 vs. 11.41 g·m−2·h−1, p < 0.001) were significantly higher at
psoriatic plaques than in uninvolved psoriatic skin and healthy volunteers, respectively, while SCH
was lower (9.71 vs. 44.64 vs. 40.00 AU, p < 0.001). After fifteen phototherapy sessions, TEWL
(–5.19 g·m−2·h−1, p = 0.016) decreased while SCH (+7.01 AU, p = 0.013) and erythema (+30.82 AU,
p = 0.083) increased at psoriatic plaques. An erythema increase exceeding 53.23 AU after the first
phototherapy session, with a sensitivity of 71.4% and specificity of 84.2%, indicates that a patient may
improve Psoriasis Area and Severity Index (PASI) by ≥3 points after fifteen phototherapy sessions. In
conclusion, phototherapy improves epidermal barrier function in psoriatic patients and the erythema
increase after one phototherapy session could help doctors select psoriasis patients who are more
likely to respond to phototherapy.
Keywords: phototherapy; psoriasis; skin barrier; skin physiology; skin homeostasis
1. Introduction
Psoriasis is a chronic, recurrent, multisystemic inflammatory disease [1] caused by
a combination of immunological imbalances, genetic associations, and environmental
factors [2]. Its prevalence around the word has been estimated at between 0.51% and
11.43% [3]. Psoriasis is considered a major global health problem [4]. Although the skin
manifestations are often the only recognized symptoms of psoriasis [5], this disease is
associated with multiple comorbidities [6–9] and impacts the patient’s quality of life [5,10].
Moreover, the economic burden of psoriasis is high, as in Europe the annual total cost per
patient is EUR 6000–12,000 [11].
Multiple treatments are effective for psoriasis, including topical medicines, oral sys-
temic prescriptions, phototherapy, and biologics [12]. Nevertheless, it is not known which
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type of patient would respond best to each treatment [13]. Moreover, tools to assess disease
severity and treatment effectiveness are subjective [14]. Thus, there is a need to develop
techniques to help physicians select the most appropriate cost-effective therapy for each
patient [15].
Phototherapy is an effective, safe, and low-cost therapy for mild–moderate psoriasis,
although many medical appointments are needed to see an improvement [16]. Several
types of light and lasers have been developed to treat psoriasis, the narrowband ultraviolet
light B (NB-UVB) being the most frequently used. NB-UVB wavelengths ranges from
311 to 313 nm. The starting dose is based on skin phototype or minimal erythema dose
(MED), and two or three sessions per week are recommended [17]. Selecting the right
patient profile for this treatment and accurately assessing disease severity would improve
patient satisfaction and healthcare spending [13]. It would also be interesting to predict the
response to assess home phototherapy effectiveness [18]. As the development of psoriasis
plaques results from the deregulation of epidermal keratinocytes and immunity cells [19]
and the phototherapy’s beneficial effect on psoriasis lesions is explained by it blocking
epidermal hyperproliferation and an immunomodulatory effect [20], objective changes
in the epidermal barrier function may help to select the right psoriasis patients for pho-
totherapy treatment and to assess disease improvement. Epidermal barrier dysfunction in
psoriasis patients has previously been reported, assessed by an increase in transepidermal
water loss (TEWL) and a decrease in stratum corneum hydration (SCH) [21,22]. To date,
only three studies have evaluated the variations in epidermal barrier function following
phototherapy, displaying an improvement in TEWL and SCH [23–25].
Thus, the aims of this study are (1) to compare epidermal barrier function and skin
homeostasis of healthy volunteers, uninvolved psoriatic skin, and psoriatic plaques, (2) to
assess changes in epidermal barrier function and skin homeostasis after one session of
phototherapy, (3) to assess changes in epidermal barrier function and skin homeostasis
after fifteen phototherapy sessions, and (4) to explore potentially predictive values in
epidermal barrier function and skin homeostasis to assess clinical improvement after
fifteen phototherapy sessions.
2. Materials and Methods
2.1. Design
A cross-sectional study was conducted to evaluate epidermal barrier function and
skin homeostasis disparities between healthy skin, uninvolved psoriatic skin, and psori-
atic plaques.
A prospective observational study was carried out on patients with psoriasis to assess
epidermal barrier function and skin homeostasis following fifteen phototherapy sessions.
Psoriatic patients were exposed to fifteen phototherapy sessions, while healthy volunteers
were only reviewed after this period of time without being exposed to phototherapy.
2.2. Setting
This study was conducted between September 2019 and March 2020 in the Dermatol-
ogy Department of the Hospital Universitario Virgen de las Nieves in Granada, Spain.
2.3. Study Population
Inclusion Criteria:
• Patients with established clinical diagnosis of active moderate-to-severe plaque-
type psoriasis (minimum Psoriasis Area and Severity Index (PASI) score of 4) [1]
selected by clinical criteria to attend phototherapy treatment with UVB narrowband
(NB-UVB) [16].
• Controls were healthy volunteers, gender- and age-matched (±3 years) with psoriasis
patients. These volunteers were people who attended the Dermatology Department
for trivial conditions such as melanocytic nevi or seborrheic keratoses. The same
criteria were used to select the non-exposed group in the prospective study.
J. Clin. Med. 2021, 10, 3897 3 of 11
Exclusion Criteria:
• For psoriasis patients, currently having non-plaque forms of psoriasis.
• For healthy volunteers, having previous personal or family history of any inflamma-
tory skin disease.
• Clinical infection on the treatment area.
• History of cancer or an immunocompromised disease.
• Not signing the informed consent form.
2.4. Follow-Up and Exposure
Exposed subjects were evaluated before and after receiving the first phototherapy
session and before and after the 15th phototherapy session. The starting dose for NB-
UVB therapy and the dosage schedule were based on skin phototype following the current
guidelines [17]. The frequency was two or three times a week depending on the patient’s avail-
ability. Non-exposed subjects were evaluated twice, on the same days as their exposed pair.
2.5. Variables
• Clinical and sociodemographic variables. Gender, age, smoking and alcohol habit,
psoriasis family history, and use of emollients were gathered by means of clinical
interview. Psoriasis severity was assessed by the PASI and the body surface area (BSA).
Every study patient was also evaluated with the Dermatology Life Quality Index
(DLQI). Information about disease duration, previous treatment, the previous number
of phototherapy sessions, session dose, and total cumulative dose was also collected.
• Epidermal barrier function variables. Homeostasis parameters related to epidermal
barrier function and skin homeostasis were measured. SCH (in arbitrary units, using
Corneometer®CM825), TEWL (in g·m−2·h−1, using Tewameter®TM300), pH (using
Skin-pH-Meter®PH905), erythema index (in arbitrary units, using Mexameter®MX18),
sebum (in arbitrary units, usingSebumeter®SM815), and skin temperature (in ◦C,
using Skin-ThermometerST500) were measured by a Multi Probe Adapter (MPA,
Courage + Khazaka electronic GmbH, Köln, Germany). Total antioxidant capac-
ity (TAC) was measured using eBQC® electrochemical method (Bioquochem S.L.
(BQCkit), Asturias, Spain), and expressed in microcoulombs. TAC is divided into two
sections: fast antioxidants (Q1), which have a lower oxidation potential, and slow
antioxidants (Q2) [26]. All variables were measured at a psoriatic plaque on the elbow
and at an uninvolved skin area near the elbow in psoriatic patients, while healthy
subjects were measured at a skin area on their elbows. All parameters were measured
ten times for each area, using their average for analysis. The measurements were
taken in the same room. The average ambient air temperature at the time of the study
was 22 ± 1◦C, and the average ambient air humidity was 45% ± 3%.
2.6. Statistical Analysis
Descriptive statistics were used to present the sample characteristics. Continuous data
were expressed as the mean ± standard deviation. The absolute and relative frequency
distributions were estimated for qualitative variables. The Shapiro–Wilk test was used to
check the normality of data distribution, and Levene’s test was used to check the homo-
geneity of variance. Linear regression models were constructed to compare continuous
data between healthy skin and psoriatic patients. To predict PASI improvement after fifteen
phototherapy sessions, cut-off points were generated using ROC curves for the changes
of erythema and SCH after the first phototherapy session. To produce these ROC curves,
the sensitivities and specificities for changes of erythema and SCH values after the first
phototherapy that predict an improvement in PASI of ≥3 after the fifteenth phototherapy
session were tabulated and the graphical ROC curve was generated by plotting true posi-
tive rate (sensitivity) on the y-axis against false positive rate (1-specificity) on the x-axis for
the various values tabulated. To select the optimal cut-off point, the point nearest to the
top-left-most corner of the ROC curve was chosen, giving equal weight to the importance
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of sensitivity and specificity. A p-value of <0.05 was considered statistically significant. Sta-
tistical Analyses were performed using the SPSS package (SPSS for Windows, Version 24.0
Chicago, IL, USA: SPSS Inc.).
2.7. Ethics
This study was authorized by the ethics committee of Hospital Universitario Virgen
de las Nieves. The nature of the study was explained to all participants, who agreed to
participate through verbal and written consent. The measurements taken were noninvasive,
and patient data were kept confidential. All experiments were done in accordance with
relevant guidelines and regulations.
3. Results
3.1. Skin Homeostasis Parameters between Healthy Participants and Psoriatic Patients
The study included 76 participants, consisting of 38 psoriatic patients and 38 healthy
participants, Supplementary Table S1.
Differences in skin homeostasis parameters between healthy skin, uninvolved, and
involved psoriatic skin before phototherapy were found, Table 1. Lower TEWL values
were found in healthy skin compared with uninvolved psoriatic skin and psoriatic plaques
(11.41 vs. 11.44 vs. 18.23 g·m−2·h−1, p < 0.001). Higher SCH values were observed in
healthy skin compared with uninvolved psoriatic skin and psoriatic plaques (40.00 vs.
44.64 vs. 9.71 AU, p < 0.001). Lower temperature values were detected in uninvolved
psoriatic skin than at psoriatic plaques (30.40 vs. 31.25 ◦C, p < 0.001). Lower erythema
index was found in healthy skin than in uninvolved psoriatic skin and psoriatic plaques
(284.52 vs. 291.12 vs. 401.09 AU, p < 0.001). Higher total antioxidant capacity was observed
in uninvolved psoriatic skin than at psoriatic plaques (6.33 vs. 5.54 uC, p = 0.014). No
differences were found in pH or sebum.










p * p ** p ***
TEWL (g·m−2h−1) 11.41 (6.63) 11.44 (8.11) 18.23 (9.46) 0.792 <0.001 ** <0.001 ***
SCH (AU) 40.00 (10.50) 44.64 (12.49) 9.71 (9.81) 0.073 <0.001 ** <0.001 ***
Temperature (◦C) 30.92 (1.04) 30.40 (1.34) 31.25 (1.59) 0.080 0.280 <0.001 ***
Erythema (AU) 284.52 (55.54) 291.12 (75.43) 401.09 (64.51) 0.574 <0.001 ** <0.001 ***
pH 5.98 (0.63) 5.86 (0.64) 5.91 (0.47) 0.321 0.301 0.728
Sebum (AU) 27.91 (26.95) 26.97 (30.50) 30.14 (30.38) 0.957 0.056 0.386
Q1 (uC) 0.86 (0.2) 1.15 (0.46) 0.96 (0.45) 0.001 * 0.176 0.001 ***
Q2 (uC) 4.30 (1.37) 5.20 (1.85) 4.57 (2.16) 0.028 * 0.565 0.026 ***
QT (uC) 5.16 (1.53) 6.33 (2.26) 5.54 (2.53) 0.015 * 0.474 0.014 ***
AU, arbitrary units; Q1, fast antioxidant capacity; Q2, slow antioxidant capacity; QT, total antioxidant capacity; SCH, stratum corneum
hydration; TEWL, transepidermal water loss; uC, microcoulombs. The data are expressed as means (standard deviation). * p-value after
using a linear regression model adjusted by emollient use to compare homeostasis parameters between healthy skin and uninvolved
psoriatic skin at baseline. ** p-value after using a linear regression model adjusted by emollient use to compare homeostasis parameters
between healthy skin and psoriatic plaques at baseline. *** p-value after using Student’s t-test for paired samples to compare homeostasis
parameters between uninvolved psoriatic skin and psoriatic plaques at baseline.
3.2. Differences in Skin Homeostasis Parameters after One Phototherapy Session
Skin homeostasis parameters were modified after one phototherapy session, Table 2.
TEWL did not change at psoriatic plaques or in uninvolved skin after one phototherapy
session. The effect of phototherapy on SCH values was different depending on the skin
involvement. It was observed that SCH increased by 2.45 ± 0.72 AU (p = 0.002) at psoriatic
plaques (but SCH was not modified in uninvolved skin (p = 0.126).
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p * p ** p ***
TEWL (g·m−2h−1) 10.78 (8.84) 17.72 (8.46) −0.66 (0.87) −0.52 (0.94) <0.001 * 0.45 0.568
SCH (AU) 42.78 (11.26) 12.16 (10.77) −1.86 (1.19) 2.45 (0.72) <0.001 * 0.126 0.002 ***
Temperature (◦C) 30.54 (1.54) 31.49 (1.42) 0.14 (0.13) 0.24 (0.1) <0.001 * 0.297 0.016 ***
Erythema (AU) 294.11 (78.14) 432.51 (81.91) 2.98 (6.19) 31.42 (8.30) <0.001 * 0.633 0.001 ***
pH 5.84 (0.54) 6.04 (0.51) −0.03 (0.11) 0.13 (0.18) 0.081 0.815 0.1
Sebum (AU) 30.21 (27.40) 27.71 (17.19) 0.97 (3.65) −3.41 (3.84) 0.571 0.792 0.381
Q1 (uC) 1.09 (0.32) 0.93 (0.39) −0.05 (0.07) −0.03 (0.06) 0.010 * 0.42 0.66
Q2 (uC) 5.00 (1.31) 4.51 (1.57) −0.18 (0.26) −0.09 (0.24) 0.026 * 0.494 0.744
QT (uC) 6.09 (1.55) 5.44 (1.91) −0.21 (0.32) −0.11 (0.28) 0.013 * 0.505 0.703
AU, arbitrary units; Q1, fast antioxidant capacity; Q2, slow antioxidant capacity; QT, total antioxidant capacity; SCH, stratum corneum
hydration; TEWL, transepidermal water loss; uC, microcoulombs. The data is expressed are means (standard deviation). * p-value after
using Student’s t-test for paired samples to compare homeostasis parameters between uninvolved psoriatic skin and psoriatic plaques after
one phototherapy session. ** p-value after using Student’s t-test for paired samples to compare homeostasis parameters in uninvolved
psoriatic skin before and after one phototherapy session. *** p-value after using Student’s t-test for paired samples to compare homeostasis
parameters at psoriatic plaques before and after one phototherapy session.
Temperature increased by 0.24 ± 0.10 ◦C at psoriatic plaques (p = 0.016). The erythema
index increased by 31.42 ± 8.30 AU (p < 0.001) at psoriatic plaques, but no changes were
observed in uninvolved skin.
Total antioxidant capacity was not modified at psoriatic plaques or in uninvolved skin
after one phototherapy session. No differences in pH or sebum were observed.
3.3. Skin Homeostasis Changes after Follow-Up
The prospective study included 76 subjects, where 52 (68.42%) met the requirements
(26 psoriatic patients and 26 healthy participants). The mean session dose at baseline was
0.46 (0.31) J. Homeostasis parameters changed after follow-up, Table 3. TEWL decreased
by 3.50 ± 1.41 g·m−2·h−1 in uninvolved skin (p = 0.021) and by 5.19 ± 2.00 g·m−2·h−1 at
psoriatic plaques (p = 0.016). No effect was observed in healthy non-exposed skin. SCH
increased by 7.01 ± 2.63 AU at psoriatic plaque (p = 0.013), while no changes were observed
in healthy skin.
Temperature increased after phototherapy by 1.5 ± 0.26 ◦C in uninvolved skin
(p < 0.001) and by 1.42 ± 0.28 ◦C at psoriatic plaques (p < 0.001), while it did not change in
healthy non-exposed skin. Erythema increased by 31.83 ± 17.06 AU in uninvolved skin
(p = 0.007), and an almost significant increase of 30.82 ± 17.06 AU was also observed at
psoriatic plaques (p = 0.087), Figure 1.
3.4. Skin Homeostasis Predicts PASI Improvement
After follow-up, PASI decreased by 3.13 ± 3.13 points, so patients were placed in two
groups: PASI reduction < 3 and PASI reduction ≥ 3. Of the patients, 73.1% (19/26) were
included in the first group and 26.9% (7/26) in the second. After the first phototherapy
session, patients with a PASI improvement ≥ 3 showed a higher erythema increase (71.08 vs.
11.54 AU, p = 0.011), and an almost significant higher SCH increase (4.69 vs. 1.40; p = 0.141)
and higher TEWL decrease (−4.97 vs. 0.86 g·m−2·h−1, p = 0.199).
A ROC curve was generated to determine an optimum cut-off value for erythema
increases after one phototherapy session, which allowed clinical improvement after 15 pho-
totherapy sessions to be predicted (area under the curve = 0.789, p = 0.026) (Figure 2A). A
value for erythema increases exceeding 53.23 AU after the first phototherapy session, with
a sensitivity of 71.4% and specificity of 84.2%, indicates that a patient may improve PASI
by ≥3 points after fifteen phototherapy sessions.
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p * p ** p ***
TEWL (g·m−2h−1) 12.18 (4.5) 8.48 (6.77) 11.98 (5.45) 0.30 (1.11) −3.50 (1.41) −5.19 (2.00) 0.786 0.021 ** 0.016 ***
SCH (AU) 45.73 (10.13) 40.78 (11.70) 17.45 (13.41) 4.18 (1.96) −6.10 (2.91) 7.01 (2.63) 0.53 0.046 ** 0.013 ***
Temperature (◦C) 30.93 (1.39) 31.49 (0.88) 32.13 (0.75) −0.01 (0.25) 1.5 (0.26) 1.42 (0.28) 0.537 <0.00 1 ** <0.001 ***
Erythema (AU) 274.13 (55.65) 329.57 (79.44) 428.15 (61.82) −13.50 (6.78) 31.83 (17.06) 30.82 (17.06) 0.68 0.007 * 0.083
pH 6.54 (0.59) 6.20 (0.28) 6.26 (0.36) 0.65 (0.18) 0.37 (0.16) 0.37 (0.16) 0.002 * 0.039 ** 0.039 ***
Sebum (AU) 17.27 (11.90) 35.00 (39.18) 32.26 (38.78) −10.38 (4.45) 12.83 (9.51) 7.17 (9.80) 0.028 * 0.190 0.472
Q1 (uC) 0.72 (0.27) 0.87 (0.25) 0.85 (0.30) −0.17 (0.04) −0.39 (0.09) −0.22 (0.11) <0.001 * <0.001 ** 0.059
Q2 (uC) 3.39 (1.20) 4.32 (1.37) 4.07 (1.20) −1.03 (0.26) −1.24 (0.43) −1.01 (0.49) 0.001 * 0.009 * 0.049 *
QT (uC) 4.13 (1.42) 5.44 (1.57) 4.90 (1.43) −1.18 (0.27) −1.36 (0.49) −1.23 (0.57) <0.001 * 0.011 * 0.041 *
AU, arbitrary units; Q1, fast antioxidant capacity; Q2, slow antioxidant capacity; QT, total antioxidant capacity; SCH, stratum corneum hydration; TEWL, transepidermal water loss; uC, microcoulombs. The data
are expressed as means (standard deviation). * p-value after using Student’s t-test for paired samples to compare homeostasis parameters in healthy skin before and after the follow-up. ** p-value after using
Student’s t-test for paired samples to compare homeostasis parameters in uninvolved psoriatic skin before and after fifteen phototherapy sessions. *** p-value after using Student’s t-test for paired samples to
compare homeostasis parameters at psoriatic plaques before and after fifteen phototherapy sessions.
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Figure 1. Homeostasis skin parameter in healthy skin, uninvolved psoriatic skin, and psoriatic
plaques before and after follow-up. AU, arbitrary units; SCH, stratum corneum hydration; TEWL,
transepidermal wate loss; uC, microco lombs. * p-value after using a lin ar regre sion model
adjusted by emollient use to com are homeostasis ar meters between control and uninvolved
psoriatic skin before phototherapy. ** p-valu after using a linear regression model adjus ed by
emollient u e t compare homeostasis par meters between control and psoriatic plaques before
phototherapy. *** p-value after using Student’s t-test for paired samples to compare homeostasis
parameters between uninvolved psoriatic skin and psoriatic plaques before phototherapy. Only
p-values of <0.05 are shown.
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Figure 2. Receiver operating characteristic (ROC) curve for the values of erythema increases after one
phototherapy session. (A) A receiver operating characteristic (ROC) curve was created to determine
the optimal cut-off value of erythema increases after one phototherapy session to predict PASI
improvement in patients with psoriasis after fifteen phototherapy sessions (area under curve = 0.789,
p = 0.026). An erythema increase exceeding 53.23 AU after the first phototherapy session had high
probability of improving PASI by ≥3 points after fifteen phototherapy sessions (sensitivity = 71.4%;
specificity = 84.2%). (B) A rec iver operating characteristic (ROC) curve was created to determine
the ptimal cut-off v lue of stratum corneum h drati n (SCH) increases after one phototherapy
session to predict PASI improvement in patients with psoriasis after fifteen phototherapy sessions
(area under curve = 0.692, p = 0.140). An SCH increase exceeding 1.06 AU after the first phototherapy
session had high probability of improving PASI by ≥3 points after fifteen phototherapy sessions
(sensitivity = 71.4%; sp cificity = 63.8%).
SCH increases were also higher in patients with PASI improvement ≥ 3. An ROC
curve was generated to determine an optimum cut-off value for SCH increase after one
phototherapy session, which allowed clinical improvement after 15 phototherapy sessions
to be predicted (area under the curve = 0.692, p = 0.1402) (Figure 2B). A value for SCH
increases exceeding 1.06 AU after the first phototherapy session, with a sensitivity of 71.4%
and specificity of 63.8%, indicates that a patient may improve PASI by ≥3 points after
fifteen phototherapy sessions.
After calculating the different cut-off levels, we evaluated whether combined val-
ues may also predict clinical improvement. Patients with erythema increase > 53.23 AU
and SCH increase > 1.06 AU after the first phototherapy session may improve PASI
by ≥3 after 15 phototherapy sessions, with a sensitivity of 57.1% and a specificity of 94.7%
(Supplementary Table S2).
4. Discussion
Differences in skin homeostasis parameters between healthy skin, uninvolved pso-
riatic skin, and psoriatic plaques have been observed. After one phototherapy session,
temperature, erythema, and SCH increased at psoriatic plaques. Moreover, after fifteen
phototherapy sessions, decreased TEWL and increased SCH and temperature levels at
psoriatic plaques were observed. Phototherapy could improve epidermal barrier function
and skin homeostasis in psoriatic patients, and erythema increases after one phototherapy
session could help clinicians select psoriasis patients with more probability of responding
to phototherapy.
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In agreement with previous reports, it has been observed that the whole epidermal
barrier is affected in psoriatic patients, not only at psoriatic plaques [27]. Other research
also found higher TEWL at psoriatic plaques than in uninvolved psoriatic skin and healthy
controls [21,22,27] and lower SCH values at psoriatic plaques than in uninvolved psoriatic
skin and healthy controls [21,27,28]. The differences in TEWL and SCH values between
psoriatic plaques and uninvolved psoriatic skin may be explained by a low AQP3 expres-
sion in plaques [29]. Temperature and erythema were also higher at psoriatic skin, probably
due to its inflammatory pathogenesis [30]. Moreover, TEWL and temperature at psoriatic
plaques were noted as useful tools for evaluating psoriasis severity [27].
The role of phototherapy on epidermal barrier function and skin homeostasis is not
well known. Our results found an improvement in epidermal barrier function and skin
homeostasis after phototherapy. Recently, it has been observed that SCH decreased, and
TEWL, erythema, and temperature increased at psoriatic plaques after only one photother-
apy session [25]. Moreover, it was shown that phototherapy increased SCH and decreased
TEWL after fourteen [24] and twenty-four [23] phototherapy sessions, without information
regarding other skin homeostasis parameters. Our study found increased SCH at psori-
atic plaques following only one phototherapy session and increased SCH and decreased
TEWL at psoriatic plaques after fifteen phototherapy sessions. Moreover, in contrast with
previous studies, we also included a non-exposed group with follow-up to prove that
changes in SCH are not because of time. Changes in SCH might be due to the inhibition of
epidermal hyperproliferation caused by phototherapy [20,31]. SCH and TEWL changes
were greater at psoriatic plaques than in uninvolved psoriatic skin, which might underline
a local effect on psoriasis plaques [32,33]. Temperature and erythema index rose after
the phototherapy session, in agreement with previous reports [25,34–36]. Assessment of
temperature and erythema increase may help clinicians optimize phototherapy to treat
patients with an effective dosage without adverse events. The pH increased in healthy
skin, uninvolved psoriatic skin, and psoriatic plaques, suggesting that time may have an
effect on pH changes. Antioxidant capacity also decreased in healthy skin, uninvolved
psoriatic skin, and psoriatic plaque. This fact might mean that the time have also an impact
in antioxidant capacity or that the sticks used might lose their capacity to measure the
antioxidant capacity along the time. There is little information regarding the effect of
phototherapy on antioxidant capacity. Oxidative stress has been evaluated by measuring
different parameters of a blood sample, with controversial results. Darlenski et al. found a
slight decrease in the detoxifying activity of catalase without significant differences after
phototherapy [24]. On the other hand, Pektas et al. observed total oxidant status and oxida-
tive stress index increased after phototherapy [37]. Our results showed total antioxidant
capacity decreases after phototherapy, in agreement with this research by Pektas.
Brazzelli et al. suggested that SCH improvement at psoriatic plaques might precede
clinical improvement [23]. As far as we know, it is not known which parameters might pre-
dict clinical improvement in psoriatic patients treated with phototherapy. We observed that
SCH changes after one phototherapy session might predict PASI improvement after fifteen
phototherapy sessions. Moreover, a value for erythema increases exceeding 53.23 AU after
the first phototherapy session, with a sensitivity of 71.4% and specificity of 84.2%, indicates
that a patient may improve PASI by ≥3 points after fifteen phototherapy sessions. This
research could help clinicians select psoriatic patients for phototherapy treatment. There-
fore, patients who do not reach this value of erythema after the first session can be treated
with another therapeutic alternative. Moreover, this research would also be interesting for
selecting candidates for home phototherapy, as patients who have an erythema increase
exceeding 53.23 AU after the first phototherapy session may improve during treatment.
This study has some limitations. (1) The variation of the homeostasis parameters
depending on external conditions. Nevertheless, to improve outcome reliability, all partici-
pants were measured by the same researcher in the same room and the ambient conditions
were measured. (2) The loss of patients observed during follow-up as COVID-19 broke out
during the follow-up period and the activity of dermatology practices was greatly reduced.
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5. Conclusions
As far as we know, this is the first study to propose a cut-off point in erythema increases
after one phototherapy session to select psoriasis patients with more likelihood of respond-
ing to fifteen phototherapy sessions. This could increase the treatment’s cost-effectiveness
and reduce indirect costs and hospital visits for patients with probable low response.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/jcm10173897/s1, Table S1. Characteristics of the participants included in the study. Table S2.
Sensitivity and specificity in the prediction of clinical improvement after 15 phototherapy sessions
based on the skin homeostasis changes after one phototherapy session.
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